Abemaciclib,Trastuzumab,Fulvestrant
eli lilly,roche,Astrazeneca
['abemaciclib', 'monarch3', 'abema', 'mbc']
#monarch3 interim os results with a clear trend of benefit (67.1 vs 54.5 months) of adding #abemaciclib to ai in hr+ her2- mbc first-line setting. very impressive that 26.7% (vs. 9.6%) of abemaciclib treated pts are free of disease progression at 5 years! #esmo2022 
Medical Oncologist, Breast Cancer Program at Hospital Moinhos de Vento, Clinical Investigator at Hospital São Lucas @PUCRS, Chair @Lacog_group